Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd alone If approved, ...

HSBC, CGSI and UOBKH have kept their target price unchanged at $3.65, $3.70 and $3.58, respectively. Citi has kept its target price of $3.60, while RHB has a target price of $3.60 as well.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

New Darzelex SC quadruplet regimen approved by European Commission for newly diagnosed multiple myeloma patients.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Prosecutors allege that Dieter S. fought for pro-Russian separatists in eastern Ukraine between 2014 and 2016, participating ...

Yankees fans ejected after ripping ball from Mookie Betts’ glove during Game 4 of World Series Robert Downey Jr. says he ...

Gary Lineker will quit presenting Match of the Day at the end of the season after 26 years, the BBC appear to have confirmed ...

Five Pennsylvania counties are investigating possible fraudulent voter applications and mail-in ballot applications in the ...

The USF Pro Championships Presented by Continental Tire has announced it will increase horsepower on road and street courses ...